MetabolismNews.net

Metabolism Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Reumabase.it

The 18-month ( 78-week ) results of a phase 3 trial of Alirocumab ( Praluent ), an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published in The New Engla ...


Type 2 diabetes and obesity impair kidney function. Researchers have examined their respective contributions to urinary albumin excretion ( UAE ) and glomerular filtration rate ( GFR ) in patients wit ...


The purpose was to study whether mortality and cardiovascular morbidity differ in non-invasive ventilation (NIV)-treated patients with severe obesity-hypoventilation syndrome ( OHS ) as compared with ...


Metabolic surgery is a novel therapy for mild obesity ( BMI 30-35 Kg/m2 ) in type 2 diabetes mellitus ( T2DM ) patients. The ABCD score, which comprise age, BMI, C-peptide level, and duration of type ...


It is unclear whether an intensive program of weight loss combined with exercise prevents the onset of knee pain among those at high risk. Researchers have examined whether an intensive lifestyle in ...


Statins are the treatment of choice for dyslipidemia, primarily lowering elevated LDL-C levels and reducing the occurrence of major cardiovascular events. In June 2011, the FDA ( Food and Drug Admin ...


Adding the drug Ezetimibe to treatment with Simvastatin lowers the risk of future cardiovascular problems, including myocardial infarction and stroke, in high-risk patients with acute coronary syndrom ...


The FDA ( Food and Drug Administration ) has approved the New Drug Application ( NDA ) for Saxenda ( Liraglutide 3 mg ), the first once-daily human glucagon-like peptide-1 ( GLP-1 ) analogue for the t ...


It is unclear whether high-density lipoprotein ( HDL ) cholesterol concentration plays a causal role in atherosclerosis. A more important factor may be HDL cholesterol efflux capacity, the ability of ...


The European Medicines Agency ( EMA ) has recommended granting a marketing authorisation for Mysimba ( Naltrexone / Bupropion ) for weight management of overweight or obese adults. The medicine is rec ...


Data, published in The Lancet, from two phase 3 studies, RUTHERFORD-2 and TESLA with Evolocumab, a novel investigational low-density lipoprotein cholesterol ( LDL-C )-lowering medication, resulted in ...


Results from four Phase 3 ODYSSEY trials of Alirocumab in people with hypercholesterolemia. Alirocumab is an investigational monoclonal antibody targeting PCSK9 ( proprotein convertase subtilisin / k ...


By inhibiting apolipoprotein B ( ApoB ) synthesis, Mipomersen ( Kynamro ) can significantly reduce ApoB-containing lipoproteins in hypercholesterolemic patients. The purpose of a study was to ascer ...


Homozygous familial hypercholesterolaemia ( HoFH ) is a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol ( LDL-C ) and accel ...


A meta-analysis of individual participant data of eight prospective cohort studies from Europe and the US has investigated the association between serum 25-hydroxyvitamin D concentrations [ 25(OH)D ] ...